Cargando…
High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review
RATIONALE: Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice. PATIENT CONCERNS: We present here a 54-year-old woman with breast cancer after first line chemotherapy and s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023661/ https://www.ncbi.nlm.nih.gov/pubmed/29901634 http://dx.doi.org/10.1097/MD.0000000000011115 |
_version_ | 1783335912354086912 |
---|---|
author | Xia, Dandan Wang, Huiyu Wang, Runjie Liu, Chaoying Xu, Junying |
author_facet | Xia, Dandan Wang, Huiyu Wang, Runjie Liu, Chaoying Xu, Junying |
author_sort | Xia, Dandan |
collection | PubMed |
description | RATIONALE: Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice. PATIENT CONCERNS: We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure. DIAGNOSES: The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2). INTERVENTIONS: The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month. OUTCOMES: The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved. LESSONS: Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2− advanced breast cancer with renal metastasis after SERMs failure. |
format | Online Article Text |
id | pubmed-6023661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-60236612018-07-03 High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review Xia, Dandan Wang, Huiyu Wang, Runjie Liu, Chaoying Xu, Junying Medicine (Baltimore) Research Article RATIONALE: Endocrine therapy plays an important role in the treatment of patients with hormone receptor-positive breast cancer. Renal metastasis of breast cancer is rare in clinical practice. PATIENT CONCERNS: We present here a 54-year-old woman with breast cancer after first line chemotherapy and second line endocrinotherapy (i.e., toremifene & exemestane) failure. DIAGNOSES: The patient was rarely diagnosed breast cancer metastasis to the kidney and a positive hormone status (ER and PR) but was negative for human epidermal factor receptor 2 (HER2). INTERVENTIONS: The patient was treated with a high dose of fulvestrant (SERD; 500 mg) by intramuscular injection once per month. OUTCOMES: The patient's condition significantly improved as measured by a decrease in the renal and pulmonary masses; symptoms including dry cough and blood phlegm also improved. LESSONS: Endocrinotherapy with high-dose fulvestrant may provide benefits for patients with HR+/HER2− advanced breast cancer with renal metastasis after SERMs failure. Wolters Kluwer Health 2018-06-15 /pmc/articles/PMC6023661/ /pubmed/29901634 http://dx.doi.org/10.1097/MD.0000000000011115 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | Research Article Xia, Dandan Wang, Huiyu Wang, Runjie Liu, Chaoying Xu, Junying High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review |
title | High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review |
title_full | High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review |
title_fullStr | High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review |
title_full_unstemmed | High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review |
title_short | High-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: A case report and literature review |
title_sort | high-dose fulvestrant as third-line endocrine therapy for breast cancer metastasis to the left kidney: a case report and literature review |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023661/ https://www.ncbi.nlm.nih.gov/pubmed/29901634 http://dx.doi.org/10.1097/MD.0000000000011115 |
work_keys_str_mv | AT xiadandan highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview AT wanghuiyu highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview AT wangrunjie highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview AT liuchaoying highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview AT xujunying highdosefulvestrantasthirdlineendocrinetherapyforbreastcancermetastasistotheleftkidneyacasereportandliteraturereview |